-

BostonGene to Drive Value-Based Cancer Care Discussions at the 14th Annual AVBCC Summit and Educational Program

BostonGene to provide insights on leveraging multiomic data and advanced screening to enhance value-based cancer care, focusing on improving patient outcomes and cost effectiveness

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 14th Annual Association for Value-Based Cancer Care (AVBCC) Summit and Educational Program. The summit, scheduled for October 16 - 18 in New York City, will bring together oncology professionals, payers, and industry leaders to explore the implementation of value-based models aimed at enhancing the quality and cost effectiveness of cancer care. This year’s Summit will focus on multiomic data utilization, biomarker-driven treatment strategies, and the integration of payer metrics to advance value-based practices in oncology.

During the event, BostonGene will participate in two panel sessions:

Utilizing Multiomic Data for Impacting the Quality and Cost of Care

  • Date & time: Thursday, October 17 | 11:00 AM - 11:50 AM
  • Speakers:
    • Mark Hiatt, MD, MBA, MS, Senior Vice President of Market Access and Strategy, BostonGene
    • Anna Ogloblina, PhD, Senior Director of Market Access and Product Management, BostonGene

This session will explore current guidelines for biomarker assays and their role in informing drug selection and treatment planning for targeted therapies and immunotherapies. The session will also discuss how multiomic testing can be leveraged to monitor treatment response and how industry and payers can collaborate to develop systems that improve the quality and cost effectiveness of oncology care.

Enhancing Payer Quality Metrics through Oncology Screening

  • Date & time: Thursday, October 17 | 4:00 PM - 4:50 PM
  • Speaker:
    • Mark Hiatt, MD, MBA, MS, Senior Vice President of Market Access and Strategy, BostonGene

This discussion will cover the role of various screening assays for pan-cancer and specific cancers, discussing their immediate and long-term impacts on patient outcomes and cost effectiveness. It will also look at how advancements in oncology screening can enhance value-based care in hospital systems and payer networks.

Visit the AVBCC website for more information.

About BostonGene Corporation

BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets, and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.

Contacts

Media Contact:

BostonGene
Erin Keleher O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

BostonGene Corporation


Release Versions

Contacts

Media Contact:

BostonGene
Erin Keleher O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

Social Media Profiles
More News From BostonGene Corporation

BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol...

BostonGene Wins Three Gold Stevie® Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie® Awards in the 2026 Stevie® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology. The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective a...
Back to Newsroom